(AFMD) Affimed - Ratings and Ratios

Affimed N.V. (NASDAQ:AFMD) is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies. Headquartered in Mannheim, Germany, the company focuses on harnessing the power of innate immunity to combat various types of cancer. Its pipeline includes multiple product candidates targeting hematologic and solid tumors, with a strong emphasis on bispecific antibodies and innate cell engagers (ICEs).

The companys lead candidate, AFM13, has demonstrated clinical activity in CD30-positive lymphomas, including Hodgkin lymphoma and peripheral T-cell lymphoma. AFM24, a tetravalent, bispecific EGFR/CD16A-binding ICE, is currently in Phase I/II clinical trials for advanced cancers, showcasing its potential to engage both innate and adaptive immune responses. AFM28, another ICE, is in preclinical development for acute myeloid leukemia (AML), while AFM32 is being developed for solid tumors. These candidates highlight Affimeds commitment to addressing unmet medical needs in oncology.

Affimed has established strategic collaborations to accelerate its pipeline. Its partnership with Artiva Biotherapeutics focuses on combining AFM13 with AlloNK cells for enhanced therapeutic outcomes. Additionally, collaborations with Roivant Sciences and Genentech aim to develop novel ICE molecules, including AFM32, and NK cell engager-based therapies, respectively. These partnerships underscore Affimeds dedication to innovation and its position as a leader in the immuno-oncology space.

Founded in 2000, Affimed N.V. has built a robust portfolio of intellectual property and a strong research and development foundation. Its focus on precision immunotherapy and its progress in clinical trials position it as a key player in the biotechnology industry, with a mission to improve outcomes for patients with debilitating cancers.